Haemonetics (NYSE: HAE) reported Q4 EPS of $0.37, $0.09 worse than the analyst estimate of $0.46. Revenue for the quarter came in at $243.2 million versus the consensus estimate of $245.08 million.

For earnings history and earnings-related data on Haemonetics (HAE) click here.